Get access

BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report

Authors


  • Funding sources: none.

  • Conflicts of interest: J.C.B. is on the ad board and speakers’ bureau for Roche and GlaxoSmithKline.

No abstract is available for this article.

Ancillary